Effects of orally administered ethyl ester of eicosapentaenoic acid (EPA; C20:5, omega-3) on PGI2-like substance production by rat aorta.
A highly purified ethyl ester of EPA (EPAEE) (74%) was manufactured from sardine oil. Sixty mg/kg/day of EPAEE was given orally to male Wistar rats for 8 weeks. No side effect or toxicity from the administration of EPAEE was observed. Plasma EPA concentration and the ratio of EPA to arachidonic acid were significantly increased, compared with control Wistar rats. An enhancement of PGI2-like substance production by aortas obtained from rats fed EPAEE was noted. Conversion of EPA to delta 17-6-keto-PGF1 alpha, a stable metabolite of PGI3, could not be detected by an incubation study of 14C-EPA and aortas either from rats fed EPAEE or from control rats. Therefore, PGI2-like substance produced by rat aorta is most likely to be PGI2 itself and not PGI3.
D015121:6-Ketoprostaglandin F1 alpha / Q000032:analysis; D000284:Administration, Oral; D000818:Animals; D001013:Aorta, Thoracic / Q000378:metabolism*; D016718:Arachidonic Acid; D001095:Arachidonic Acids / Q000097:blood; D015118:Eicosapentaenoic Acid / Q000031:analogs & derivatives*; D011464:Epoprostenol / Q000378:metabolism*; D005227:Fatty Acids / Q000097:blood; D005231:Fatty Acids, Unsaturated / Q000008:administration & dosage / Q000494:pharmacology*; D008055:Lipids / Q000097:blood; D008297:Male; D010974:Platelet Aggregation; D011453:Prostaglandins / Q000378:metabolism*; D051381:Rats; D011919:Rats, Inbred Strains
D001095:Arachidonic Acids; D005227:Fatty Acids; D005231:Fatty Acids, Unsaturated; D008055:Lipids; D011453:Prostaglandins; D016718:Arachidonic Acid; D015121:6-Ketoprostaglandin F1 alpha; C035276:eicosapentaenoic acid ethyl ester; D015118:Eicosapentaenoic Acid; D011464:Epoprostenol